Description

Description

Glem-Lin 25/5mg is a fixed-dose combination medicine manufactured by NABIQASIM Industries, containing Empagliflozin 25mg and Linagliptin 5mg. This higher-strength formulation combines two complementary mechanisms of action: Empagliflozin, an SGLT2 inhibitor that promotes glucose excretion through the kidneys, and Linagliptin, a DPP-4 inhibitor that enhances the body’s natural insulin response while suppressing excess glucose production. This combination is often prescribed for patients who need stronger glycemic control than the lower-dose formulation provides, offering a single-tablet solution for more advanced type 2 diabetes management.

Ingredients

Each film-coated tablet contains Empagliflozin 25mg and Linagliptin 5mg, along with pharmaceutical-grade excipients to ensure tablet stability, consistent drug release, and shelf life.

Dosage Form

Glem-Lin 25/5mg is available as an oral film-coated tablet, packaged in a strip of 14 tablets for a structured treatment course.

Uses

Glem-Lin 25/5mg is prescribed to:

• Provide intensified blood glucose control in adults with type 2 diabetes mellitus
• Serve as an upgraded dose for patients not achieving target sugar levels on lower-strength therapy
• Support combination treatment alongside diet, exercise, and lifestyle changes
• Reduce pill burden by combining two glucose-lowering mechanisms in one tablet

Your doctor will assess your kidney function, current glycemic control, and treatment history before prescribing this strength.

How To Use

Take Glem-Lin 25/5mg exactly as directed by your physician, typically once daily in the morning, with or without food. Swallow the tablet whole with water without crushing or chewing it. Follow your prescribed dietary and exercise plan alongside this medicine for optimal results. Do not increase, decrease, or stop your dose without medical advice, as sudden changes may disrupt blood sugar stability.

Side Effects

Patients may experience side effects such as urinary tract infections, genital yeast infections, increased urination, or mild dehydration linked to Empagliflozin’s glucose-elimination effect. Linagliptin-related effects may include headache, nasopharyngitis, or mild digestive discomfort. Less common effects include low blood pressure, joint discomfort, or hypoglycemia when combined with insulin or other diabetes medicines. Seek urgent medical care if you notice signs of ketoacidosis, severe dehydration, or allergic reactions such as swelling or difficulty breathing.

Pregnancy & Breastfeeding

Glem-Lin 25/5mg is generally not recommended during pregnancy due to limited safety data, and alternative treatments are typically preferred by physicians. It remains unclear whether its components pass into breast milk, so nursing mothers should seek medical advice before use to protect infant safety.

Storage Instructions

Store Glem-Lin 25/5mg tablets in a cool, dry location away from direct sunlight and moisture, at a temperature below 30°C. Retain tablets in their original blister packaging and keep out of reach of children.

FAQs

Q: When is the 25/5mg strength prescribed over 10/5mg?
A: This higher dose is typically prescribed when blood sugar control needs to be intensified beyond the lower-strength formulation.

Q: Does this medicine increase the risk of dehydration?
A: Yes, due to increased urination from Empagliflozin, adequate fluid intake is important during treatment.

Q: Can I switch directly from Glem-Lin 10/5mg to 25/5mg?
A: Dose changes should only be made under your doctor’s supervision based on your blood sugar response.

Q: Is monitoring required while on this medicine?
A: Yes, regular monitoring of blood sugar and kidney function is recommended throughout treatment.

Disclaimer

Always use this medicine strictly according to your doctor’s instructions and prescribed dosage.